BioAge Labs, Inc. (BIOA) intrinsic value & 10-year financials
BioAge Labs, Inc. (BIOA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $9.0M, with an average return on invested capital of -60.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.84
- Market cap
- $173.9M
- Revenue (FY2025)
- $9.0M
- ROIC (10-yr avg)
- -60.0%
- Free cash flow (FY2025)
- -$82.3M
BIOA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $9.0M | -$80.6M | -$2.24 | -$82.3M | -1031.5% | -283.6% |
| FY2024 | $0 | -$71.1M | -$6.63 | -$51.9M | — | 76.8% |
| FY2023 | — | -$63.9M | -$38.17 | -$37.5M | — | 26.8% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BioAge Labs, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BioAge Labs, Inc. has earned high returns on invested capital, averaging 33.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BioAge Labs, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BioAge Labs, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.